State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou 510060, China.
Med Oncol. 2011 Dec;28 Suppl 1:S197-203. doi: 10.1007/s12032-010-9696-8. Epub 2010 Nov 17.
Na+-dependent glucose cotransporter (SGLT1), reported overexpression in tumor tissues while its clinical significance was not established, and epidermal growth factor receptor (EGFR) with potential relation to SGLT1 were studied in order to investigate their clinical significance in colorectal cancer (CRC). Eighty-five patients of CRC who received chemotherapy in Sun Yat-sen Cancer Center from March 1st 2005 to December 31st 2008 were enrolled. SGLT1 and EGFR expression in these cancer tissues and 28 normal tissues were tested by immunohistochemistry. (1) Expression of SGLT1 (P = 0.00) and EGFR (P = 0.01) in cancer tissues was higher than that in normal tissues. (2) Their expression related with clinical stage (P = 0.03 and P = 0.02), but not with other clinical characteristics. (3) For first-line chemotherapy, expression of SGLT1 (P = 0.06 and P = 0.21) and EGFR (P = 0.37 and P = 0.31) had no influence on objective response rate (ORR) and disease control rate (DCR). EGFR overexpression was associated with lower disease-free survival (P = 0.00) and overall survival (P = 0.01), while SGLT1 did not (P = 0.79 and P = 0.34). Conclusions Both SGLT1 and EGFR overexpression in CRC was related to higher clinical stages. SGLT1 had a potential impact on the ORR of first-line chemotherapy in CRC. EGFR was associated with prognosis, while SGLT1 did not.
钠依赖型葡萄糖共转运蛋白（SGLT1）在肿瘤组织中呈过表达，但其临床意义尚未确定，而表皮生长因子受体（EGFR）与 SGLT1 可能有关，因此研究它们在结直肠癌（CRC）中的临床意义。本研究纳入了 2005 年 3 月 1 日至 2008 年 12 月 31 日在中山大学肿瘤防治中心接受化疗的 85 例 CRC 患者。采用免疫组化法检测这些癌组织和 28 例正常组织中 SGLT1 和 EGFR 的表达。（1）癌组织中 SGLT1（P = 0.00）和 EGFR（P = 0.01）的表达高于正常组织。（2）它们的表达与临床分期有关（P = 0.03 和 P = 0.02），但与其他临床特征无关。（3）对于一线化疗，SGLT1（P = 0.06 和 P = 0.21）和 EGFR（P = 0.37 和 P = 0.31）的表达对客观缓解率（ORR）和疾病控制率（DCR）没有影响。EGFR 过表达与无疾病生存期（P = 0.00）和总生存期（P = 0.01）降低相关，而 SGLT1 则无此相关性（P = 0.79 和 P = 0.34）。结论 CRC 中 SGLT1 和 EGFR 的过表达均与较高的临床分期有关。SGLT1 可能对 CRC 一线化疗的 ORR 有影响。EGFR 与预后有关，而 SGLT1 则无关。
